U.S. Markets closed

Celyad (CYAD) Jumps: Stock Rises 6.8%

Zacks Equity Research
1 / 2
How Long Will The Dark Clouds Last?

Celyad SA CYAD was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, trading within a volatile range of $23.91–$29.56 in the past one-month time frame, showed a sharp increase yesterday.

The company has seen no changes when it comes to estimate revision over the past month, while the Zacks Consensus Estimate for the current quarter hasn’t been in a trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Celyad currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.  

Celyad SA Price

Celyad SA Price | Celyad SA Quote

A better-ranked stock in the Medical – Biomedical and Genetics industry is Agenus Inc. AGEN, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is CYAD going up? Or down? Predict to see what others think:Up or Down

Today's Stocks from Zacks' Hottest Strategies
 
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
 
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
 
See Them Free>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Agenus Inc. (AGEN) : Free Stock Analysis Report
 
Celyad SA (CYAD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research